Cargando…

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations

OBJECTIVE: To investigate the efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell carcinoma (mRCC) with rhabdoid (mRCC‐R) and sarcomatoid (mRCC‐S) differentiations. MATERIALS AND METHODS: In this single‐institutional cohort study, we included patients with RCC wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Kun, Duan, Pengqiang, Chen, Xusheng, Yang, Qing, Feng, Guowei, Diao, Lei, Zhang, Zhenting, Yao, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358213/ https://www.ncbi.nlm.nih.gov/pubmed/37325945 http://dx.doi.org/10.1002/cam4.6081

Ejemplares similares

Sarcomatoid renal cell carcinoma with rhabdoid features
por: Al-Saidi, Nagla Ahmed, et al.
Publicado: (2013)

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
por: Bakouny, Ziad, et al.
Publicado: (2021)

Renal Cell Carcinoma With Rhabdoid and Sarcomatoid Features Presented as a Metastatic Thigh Mass With an Unusual Immunohistochemical Profile
por: Abdou, Asmaa Gaber, et al.
Publicado: (2014)

Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically
por: Yang, Bin, et al.
Publicado: (2020)

Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
por: Udupa, Karthik S, et al.
Publicado: (2017)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report
por: Noguchi, Go, et al.
Publicado: (2018)

Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation
por: Lichtbroun, Benjamin J., et al.
Publicado: (2023)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
por: Yao, Jia-Xi, et al.
Publicado: (2018)

Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Wang, Zhaojuan, et al.
Publicado: (2023)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
por: Poddubskaya, Elena V., et al.
Publicado: (2018)

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
por: Ishihara, Hiroki, et al.
Publicado: (2017)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
por: Janisch, Florian, et al.
Publicado: (2021)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Zhi, Hong, et al.
Publicado: (2020)

Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma
por: Wang, Zhixian, et al.
Publicado: (2018)

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
por: Kakizoe, Manabu, et al.
Publicado: (2014)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma
por: Ianiro, Gianluca, et al.
Publicado: (2020)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma
por: Alimchandani, Meghna, et al.
Publicado: (2014)

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
por: Achkar, Tala, et al.
Publicado: (2017)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Surgery after combination therapy with a tyrosine kinase inhibitor and anti-PD-1 antibody in sarcomatoid hepatocellular carcinoma: case report and literature review
por: Liang, Bin, et al.
Publicado: (2023)

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

The significance of SMARCB1 in the pathogenesis of renal cell carcinoma with rhabdoid features
por: Wang, Yi-Wen, et al.
Publicado: (2021)

Metastatic renal cell carcinoma of the native kidney in a renal transplant recipient: Revisiting the era of tyrosine kinase inhibitors – Case report
por: Suso-Palau, Daniel, et al.
Publicado: (2022)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oc14pme5rb7c3kltddnv0182od